ArticleBMC psychiatry2026
Comparison of clinical features and cerebral glucose metabolism between patients with major depressive disorder and Parkinson's with depression.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhether there are differences in clinical symptoms and brain glucose metabolism between major depressive disorder (MDD) and Parkinson’s comorbid depression (DPD) is unclear. The aims of this study were to investigate the differences in characteristics in clinical and glucose metabolism between MDD and DPD and their internal correlation.
methodsWe enrolled 30 MDD patients, 25 DPD patients, and 20 Parkinson’s patients without depression (PD-ND), all of whom were evaluated by neuropsychological scales and position emission tomography (PET) imaging. We compared the differences in depressive symptoms, cognitive symptoms, and glucose metabolism imaging and analyzed metabolic characteristics and their correlation with depression.
resultsCompared with MDD, DPD has relatively mild depressive symptoms and is dominated by general systemic symptoms. Meanwhile, the cognitive impairment of DPD is more severe, mainly in executive function. Furthermore, both DPD and MDD have extended metabolism changes in the frontal and parietal lobes and the limbic system. The FDG metabolism in the left posterior medial temporal lobe was significantly lower in patients with DPD compared to those with MDD, and this reduction was positively correlated with the severity of depressive symptoms.
conclusionsMDD and DPD have some brain regions with common trends, suggesting that both of them may share a common pathophysiological basis. The specific changes, such as hypometabolism in the left primary visual cortex and right inferior lateral temporal lobe, and the hypermetabolism of the right lentiform nucleus, may contribute to the early differentiation of DPD or MDD in patients with depression. CLINICAL TRIAL NUMBER: ChiCTR2400092675 (Date of Registration: 2024-11-21).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.